Familiar Therapeutics Raises $5M Seed Led by Icehouse Ventures

Familiar Therapeutics Closes $5M Seed Round

Familiar Therapeutics, a Redwood City, California-based biotechnology company, has raised a $5 million seed round. The round was announced on October 22, 2026, and was led by Icehouse Ventures.

Investors

• Lead: Icehouse Ventures
• Participants: Pioneer Fund, BreakTHRU

What the Company Does

Familiar Therapeutics adapts medicines first developed for humans into new therapeutics for dogs and cats. The company licenses veterinary rights to drug candidates that already have years of human research behind them, then leads the animal-specific clinical development, manufacturing and FDA regulatory work needed for approval.

The model is designed to cut years off typical animal-drug development timelines by starting from candidates with existing human data rather than beginning from scratch.

Pipeline and Partnerships

Familiar Therapeutics runs a 13-program pipeline spanning oncology, neurology, cardiology, respiratory disease and immunology. The company partners with biopharma companies that retain human rights and share in veterinary sales.

Founding Team

Familiar Therapeutics was founded in May 2026 by Elizabeth Iorns and Dan Knox, co-founders of Science Exchange.

Why It Matters for Acquisition Watchers

Familiar Therapeutics is pursuing a licensing-and-development model that bridges human drug candidates into the veterinary market. The approach targets a structural inefficiency: animal-drug development timelines that can be shortened when a candidate already carries human research.

A 13-program pipeline across five therapeutic areas gives the company breadth at an early stage, while its partnership structure keeps biopharma partners invested in veterinary sales outcomes. For acquirers in animal health, veterinary pharmaceuticals or biotech platforms, Familiar Therapeutics offers a pipeline and a repeatable licensing playbook.

The $5 million seed round, led by Icehouse Ventures with participation from Pioneer Fund and BreakTHRU, funds the company as it advances animal-specific development and regulatory work. No specific program timelines, approval dates or partner names were disclosed.